Semax is the nootropic peptide with a strange double life. In Russia it is a registered medicine, used in hospitals for stroke. In the US it is an unapproved research chemical that people put in nasal sprays to sharpen focus. In July 2026 it was one of six peptides an FDA advisory panel recommended for compounding. Here is what is actually known.
Weak in humans. There are Russian clinical studies, mostly in stroke, but they are small, often not randomized or blinded, and mostly run by the institute that developed the drug. There are no Western randomized trials that we could verify. The Alzheimer’s Drug Discovery Foundation reviewed it and said well-conducted studies are lacking. The animal work is more interesting than the human work.
Semax is a synthetic peptide of seven amino acids. It takes a short piece of ACTH, a stress hormone, and adds a three-amino-acid tail (Pro-Gly-Pro) that makes it last longer. You will see it described as an “ACTH(4-10) analog” and also as “ACTH(4-7)PGP.” Both names mean the same molecule. The key point is that it keeps some of ACTH’s effects on the brain without acting like the hormone itself. It does not stimulate cortisol.
It comes as nasal drops. You will also see “N-Acetyl Semax” and “NA-Semax-Amidate” for sale. Those are gray-market modifications with no published human data and no approval anywhere.
It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow. It is registered in Russia as nasal drops in two strengths, a 0.1% solution for general and cognitive use and a 1% solution for stroke. Russian labeling lists uses including stroke, circulation-related brain problems and optic nerve disease.
Almost all of this comes from rats. The headline finding is BDNF, a growth factor that helps brain cells survive and connect. In rats, nasal Semax raised BDNF in the hippocampus by about 40%, and activity at its receptor by about 60%. That rise was short-lived, back to normal within a day in one brain region.
It also appears to influence brain chemicals. In rats it raised serotonin. Other work describes effects on dopamine signaling. And in rat stroke models, it shifted the activity of genes involved in inflammation and blood vessels.
So the mechanism story is plausible and has real lab work behind it. It has not been confirmed in people.
The most-cited human study is a 1997 Russian stroke study. Thirty patients got Semax and were compared to 80 patients on usual care. It was not randomized, not blinded, and the comparison group was not treated at the same time. The authors reported faster recovery of movement.
A later Russian study of 110 stroke patients found Semax raised BDNF in the blood, and patients with higher BDNF did better in rehab. A small 2018 pilot in 24 healthy people found a single dose changed brain scan activity. That measured brain activity, not any real-world benefit.
In rat stroke models, Semax reduced the size of brain damage and improved memory tasks. Results in Parkinson’s models were mixed.
The honest read is that the studies are small, mostly in Russian, mostly from one institute, and not independently replicated.
Focus, mental energy, mood, and recovery after concussion or stroke. It is very often paired with Selank, with Semax pitched as the “drive” half and Selank as the “calm” half. None of these uses is proven in a Western trial.
Russian sources report nasal irritation or discoloration in about 10% of users, and a rise in blood sugar in some people with diabetes. Long-term effects and drug interactions are unknown. The FDA raised concerns about immune reactions, poor characterization of what is being sold, and missing impurity data. And the FDA noted there is no published human safety data for injecting it under the skin, which some people do.
Gray-market vials have no quality control at all.
Reporting, not a recommendation. Russian labeling for general use describes a couple of drops of the 0.1% solution twice a day. For stroke, it describes more drops of the 1% solution several times a day. In the gray market, people make their own nasal sprays or inject it, usually in the hundreds of micrograms per day. Those amounts are anecdotal. We do not give mixing or injection steps.
Not FDA-approved. In 2023 the FDA placed Semax in Category 2, which blocked compounding. At the July 2026 Pharmacy Compounding Advisory Committee meeting, FDA staff recommended against it. The panel voted 8 to 5 to recommend adding it to the compounding list, for cerebral ischemia, migraine and trigeminal neuralgia. That vote is advisory. The FDA still has to finish formal rulemaking before any pharmacy can lawfully compound it. We cover that process in our post on the “Do Not Compound” list.
Sport status is unclear. Semax is not named on the WADA list. Some sites say it falls under the “non-approved substances” category, but that category may not apply to a drug that is approved in Russia. Athletes should check with USADA directly.
Is Semax FDA-approved? No. A July 2026 advisory vote recommended allowing compounding, but the FDA has not finalized it.
Is it legal in the US? It is not a controlled substance, but it is not approved, and lawful compounding is still pending.
Does it raise BDNF? In rats, briefly. In humans there is one small Russian study in stroke patients.
Does it work for stroke? It is used for stroke in Russia. The supporting studies are small and low quality.
What about N-Acetyl Semax? No published human data. Claims that it is “stronger” are not backed by evidence.
What are the side effects? Nasal irritation, possible higher blood sugar in people with diabetes, and unknown long-term effects.
Is it banned in sport? Unclear. Check with USADA.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.